Phase 1 N=40 Dose Titration Investigation of the Pharmacokinetics of Testosterone Transdermal Systems in Hypogonadal Men
Hypogonadism
Primary: Time-average (Cavg) Steady State Testosterone Concentration Over 24 Hours — 463 ng/dL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=26 10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Non-Fasting Conditions
Healthy
Primary: Cmax of Donepezil. — 15627.68; 15687.09 ng/mL
Phase 1 N=26 90 mg Fluoxetine Hydrochloride Capsules Under Non-Fasting Conditions
Healthy
Primary: Cmax of Fluoxetine. — 75.32; 69.86 ng/mL
Phase 1 N=26 10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Fasting Conditions.
Healthy
Primary: Cmax of Donepezil. — 17800.27; 17280.23 ng/mL
Phase 1 N=26 90 mg Fluoxetine Hydrochloride Capsules Under Fasting Conditions
Healthy
Primary: Cmax of Fluoxetine. — 64.17; 56.61 ng/mL
Phase 1 N=24 Venlafaxine Hydrochloride 150 mg Extended-Release Capsules Under Fasting Conditions
Healthy
Primary: Cmax of Venlafaxine. — 124.75; 117.69 ng/mL
Phase 1 N=70 Examine Plasma Concentrations of Buprenorphine Following Reapplication of Buprenorphine Transdermal System (BTDS) After Variable Application Site Rest Periods
Healthy
Primary: Period 1: AUC0-3d — 8680; 7651; 6465; 12258 pg/mL*h
Phase 1 N=6 Efalizumab to Treat Uveitis
Uveitis · Macular Edema
Primary: Number of Participants With Systemic Toxicities, Adverse Events, or Infections — 6 Participants
Phase 1 N=20 Buprenorphine Accumulation and Description of Its Metabolites During Co-Medication of Buprenorphine Transdermal System (BTDS) and Ketoconazole
Healthy
Primary: AUCt of Buprenorphine With and Without Ketoconazole. — 16354.8; 16627.9 pg/mL*h
Phase 1 N=18 Study With Candida Antigen for Treatment of Warts
Warts · HPV
Primary: Number of Participants With Clinical Resolution of Injected Wart — 9; 1; 1 Participants
Phase 1 N=16 ORAL T-6: Oral Androgens in Man-6
Contraception · Hypogonadism
Primary: Area Under the Curve-Serum T — 143; 198; 144; 384 nmol*h/L — p=<0.05
Phase 1 N=24 Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (B)
Type 2 Diabetes Mellitus
Primary: Saxagliptin Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUC[INF]) — 47.25; 48.91; 52.89…
Phase 1 N=14 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK8245 (8245-004)(COMPLETED)
Type 2 Diabetes
Primary: Number of Participants Experiencing Clinical and Laboratory Adverse Events (CAEs and LAEs) — 4; 5; 0; 0 participants
Phase 1 N=43 A Phase I Evaluation of the Safety of the TriVascular Stent-Graft System in the Treatment of Abdominal Aortic Aneurysms
Abdominal Aortic Aneurysm
Primary: Number of Participants Without a Device Related Adverse Events Within 1 Month of the Study Procedure. — 36 Participants
Phase 1 N=23 Safety, Pharmacokinetics (PK), And Hematological Activity Of AMD3100 (Plerixafor) In Subjects With Renal Impairment
Renal Impairment
Primary: Dose-Normalized Maximum Concentration of Plerixafor (Cmax) — 0.0452; 0.0388; 0.0490; 0.0475 ng/mL/ug